---
title: "Novo Nordisk's Weight Loss Blockbuster Faces Setback From US Compounding Surge, Forecast Trimmed"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/239065514.md"
description: "Novo Nordisk A/S NVO slashed its 2025 sales forecast Wednesday, citing lower-than-expected penetration of its branded GLP-1 weight loss and diabetes treatments in the U.S. market due to competition from compounded versions of the drugs."
datetime: "2025-05-07T08:05:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/239065514.md)
  - [en](https://longbridge.com/en/news/239065514.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/239065514.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/239065514.md) | [繁體中文](https://longbridge.com/zh-HK/news/239065514.md)


# Novo Nordisk's Weight Loss Blockbuster Faces Setback From US Compounding Surge, Forecast Trimmed

Novo Nordisk A/S NVO slashed its 2025 sales forecast Wednesday, citing lower-than-expected penetration of its branded GLP-1 weight loss and diabetes treatments in the U.S. market due to competition from compounded versions of the drugs.

### Related Stocks

- [Novo Nordisk A/S (NVO.US)](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

- [FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market](https://longbridge.com/en/news/281394441.md)
- [FACTBOX-Pricing and availability of Novo, Lilly's weight-loss drugs](https://longbridge.com/en/news/281413480.md)
- [Here's How Much $100 Invested In abrdn Physical Silver Shares ETF 10 Years Ago Would Be Worth Today](https://longbridge.com/en/news/281394387.md)
- [Destiny Tech100 Stock Rises After SpaceX IPO Rumors](https://longbridge.com/en/news/281415250.md)
- [BREAKINGVIEWS-SpaceX IPO will gauge market moxie more than depth](https://longbridge.com/en/news/281406751.md)